BioncoDx is developing affordable, non-invasive liquid biopsy assays for the early detection of multiple cancers, with an initial focus on lung cancer, to reach the millions who currently lack access to effective screening methods.
Low-Dose CT (LDCT) is the standard — but cost, inconvenience, and a high false positive rate mean ~80-82% of eligible patients never get screened.[1]
BioncoDx uses liquid biopsy and mass spectrometry to detect cancer-associated biomarkers — no imaging equipment, no travel, no specialist required.
Simple, comfortable sample collection that can be done in any clinical setting or at home.
Designed to be a fraction of the cost of current LDCT screening, making broad population screening economically viable.
Early research from NCI reported a false positive rate of <17% — notably lower than the roughly 25% often seen with LDCT screening.[3][4]
No special equipment or trained specialists required — designed for the clinic, the lab kit, and eventually self-administered use.
Of the 12.8M+ Americans eligible for annual lung cancer screening:
The lung cancer screening market is expanding rapidly, driven by aging populations, widening eligibility guidelines, and increasing awareness. BioncoDx is positioned to lead the next generation of this market.
Source: Fortune Business Insights. Market growing at ~9% annually; early detection segment at ~14%.
BioncoDx is developing three distinct product formats designed to reach patients across every point of care — from specialist clinics to the patient's own home.
BioncoDx's platform is built on patented biomarker technology and associated metabolites licensed from the National Cancer Institute, advanced through collaboration with Penn State University and other academic institutions. It employs liquid chromatography–mass spectrometry (LC-MS) to detect a defined panel of cancer-associated metabolites from a non-invasive liquid biopsy sample.
The technology identifies metabolite biomarkers associated with lung cancer, delivering clinically relevant information without imaging equipment, radiation, or invasive procedures. Initial validation data has been published in peer-reviewed literature.
A simple, non-invasive sample is collected — no specialized facility or equipment needed. Designed to be feasible during a routine clinical visit.
The sample is processed through liquid chromatography–mass spectrometry, precisely measuring a defined panel of cancer-associated metabolites.
A validated algorithm evaluates the biomarker profile and generates a clinically actionable result — supporting early detection and risk stratification.
Results are delivered to the ordering physician, enabling earlier intervention and follow-up — when outcomes are most impactful.
BioncoDx is advancing through a staged development pathway from initial clinical validation toward regulatory approval and broad commercial deployment.
BioncoDx brings together leading experts in oncology, mass spectrometry, and business development — united by the mission to make cancer detection more accessible.
BioncoDx is seeking sponsorship partners to advance expanded clinical trials and accelerate the path to regulatory approval. Your support directly enables broader, earlier cancer detection at scale.